Recent discussions on X about Abbott Laboratories (ABT) have centered on the company’s latest quarterly earnings and guidance updates. Posts on the platform highlight a mixed reaction to the healthcare giant’s performance, with some noting a strong earnings beat for Q2 driven by robust demand for medical devices. However, there’s notable concern over the lower-than-expected Q3 EPS guidance, which has sparked debates about future growth prospects.
Additionally, chatter on X reflects intrigue over analyst upgrades and the stock’s price movement following a dip attributed to the guidance revision. Some users have pointed out the potential for long-term value in what they describe as a resilient, high-quality business, while others remain cautious due to the near-term outlook. This dynamic has kept the conversation lively and polarized among investors tracking the stock.
Note: This discussion summary was generated from an AI condensation of post data.
Abbott Laboratories Congressional Stock Trading
Members of Congress have traded $ABT stock 10 times in the past 6 months. Of those trades, 6 have been purchases and 4 have been sales.
Here’s a breakdown of recent trading of $ABT stock by members of Congress over the last 6 months:
- REPRESENTATIVE JEFFERSON SHREVE sold up to $100,000 on 05/12.
- REPRESENTATIVE BRUCE WESTERMAN has traded it 2 times. They made 1 purchase worth up to $15,000 on 03/03 and 1 sale worth up to $15,000 on 04/21.
- REPRESENTATIVE BYRON DONALDS has traded it 2 times. They made 2 purchases worth up to $30,000 on 03/20 and 0 sales.
- REPRESENTATIVE JOSH GOTTHEIMER has traded it 4 times. They made 3 purchases worth up to $45,000 on 02/13, 01/29, 01/28 and 1 sale worth up to $15,000 on 03/06.
- SENATOR SHELLEY MOORE CAPITO sold up to $15,000 on 02/24.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
Abbott Laboratories Insider Trading Activity
Abbott Laboratories insiders have traded $ABT stock on the open market 13 times in the past 6 months. Of those trades, 0 have been purchases and 13 have been sales.
Here’s a breakdown of recent trading of $ABT stock by insiders over the last 6 months:
- ROBERT B FORD (CHAIRMAN AND CEO) sold 285,388 shares for an estimated $37,435,200
- HUBERT L ALLEN (EXECUTIVE VICE PRESIDENT) has made 0 purchases and 2 sales selling 189,788 shares for an estimated $24,342,303.
- LISA D EARNHARDT (EVP AND GROUP PRESIDENT) has made 0 purchases and 2 sales selling 91,367 shares for an estimated $12,227,296.
- DANIEL GESUA SIVE SALVADORI (EXECUTIVE VICE PRESIDENT) sold 23,771 shares for an estimated $3,054,573
- LOUIS H. MORRONE (EXECUTIVE VICE PRESIDENT) has made 0 purchases and 2 sales selling 3,755 shares for an estimated $490,326.
- SALLY E. BLOUNT sold 2,600 shares for an estimated $337,116
- ANDREA F WAINER (RETIRED EVP) sold 949 shares for an estimated $131,123
- MARY K MORELAND (EXECUTIVE VICE PRESIDENT) sold 791 shares for an estimated $109,292
- JOHN A. JR. MCCOY (VICE PRESIDENT AND CONTROLLER) sold 562 shares for an estimated $77,651
- ERIC SHROFF (Senior Vice President) sold 562 shares for an estimated $77,651
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Abbott Laboratories Hedge Fund Activity
We have seen 1,357 institutional investors add shares of Abbott Laboratories stock to their portfolio, and 1,427 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CAPITAL WORLD INVESTORS added 7,667,348 shares (+572.8%) to their portfolio in Q1 2025, for an estimated $1,017,073,712
- GAMMA INVESTING LLC removed 5,057,001 shares (-99.1%) from their portfolio in Q2 2025, for an estimated $687,802,706
- JPMORGAN CHASE & CO added 4,743,319 shares (+13.5%) to their portfolio in Q1 2025, for an estimated $629,201,265
- DZ BANK AG DEUTSCHE ZENTRAL GENOSSENSCHAFTS BANK, FRANKFURT AM MAIN added 3,831,031 shares (+394.2%) to their portfolio in Q1 2025, for an estimated $508,186,262
- GOLDMAN SACHS GROUP INC added 3,655,471 shares (+29.6%) to their portfolio in Q1 2025, for an estimated $484,898,228
- WELLINGTON MANAGEMENT GROUP LLP added 3,371,113 shares (+12.8%) to their portfolio in Q1 2025, for an estimated $447,178,139
- CAPITAL RESEARCH GLOBAL INVESTORS removed 3,362,559 shares (-6.2%) from their portfolio in Q1 2025, for an estimated $446,043,451
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Abbott Laboratories Government Contracts
We have seen $115,838,725 of award payments to $ABT over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- VISN 9 CHEMISTRY AUTOMATION COST PER RESULTS REPORTABLE: $8,212,792
- VISN1 BPA FOR IMMUNOCHEMISTRY CPRR TESTING: $4,077,450
- CHEMISTRY IMMUNOASSAY ANALYZER COST PER REPORTABLE RESULT (CPRR): $4,000,483
- CHEMISTRY ANALYZERS COST PER REPORTABLE RESULTS: $3,555,612
- LAB CHEMISTRY SERVICES: $3,039,674
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
Abbott Laboratories Analyst Ratings
Wall Street analysts have issued reports on $ABT in the last several months. We have seen 12 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Wells Fargo issued a "Overweight" rating on 07/18/2025
- BTIG issued a "Buy" rating on 07/18/2025
- Raymond James issued a "Outperform" rating on 07/18/2025
- Jefferies issued a "Buy" rating on 07/18/2025
- RBC Capital issued a "Outperform" rating on 07/15/2025
- Stifel issued a "Buy" rating on 04/17/2025
- Barclays issued a "Overweight" rating on 04/17/2025
To track analyst ratings and price targets for Abbott Laboratories, check out Quiver Quantitative's $ABT forecast page.
Abbott Laboratories Price Targets
Multiple analysts have issued price targets for $ABT recently. We have seen 15 analysts offer price targets for $ABT in the last 6 months, with a median target of $145.0.
Here are some recent targets:
- Lawrence Biegelsen from Wells Fargo set a target price of $142.0 on 07/18/2025
- Jayson Bedford from Raymond James set a target price of $141.0 on 07/18/2025
- Matthew Taylor from Jefferies set a target price of $145.0 on 07/18/2025
- Marie Thibault from BTIG set a target price of $145.0 on 07/18/2025
- Anthony Petrone from Mizuho set a target price of $135.0 on 07/18/2025
- Shagun Singh from RBC Capital set a target price of $147.0 on 07/15/2025
- David Lewis from Morgan Stanley set a target price of $137.0 on 07/15/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
